ONCAlert | 2017 San Antonio Breast Cancer Symposium

Enzalutamide Shows Promise in HR+ Breast Cancer

Denise Yardley, MD
Published Online: 1:42 PM, Thu December 7, 2017


Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.